Low rate of malignancy for BI-RADS category 3 lesions

Low rate of malignancy for BI-RADS category 3 lesions

(HealthDay)—A low malignancy rate is observed for Breast Imaging Reporting and Data System (BI-RADS) category 3 breast lesions detected by screening ultrasonography (US), according to research published in the December issue of Radiology.

Richard G. Barr, M.D., Ph.D., of Radiology Consultants in Youngstown, Ohio, and colleagues analyzed data from the American College of Radiology Imaging Network 6666 protocol to prospectively validate predefined criteria for BI-RADS category 3 detected at screening US.

The researchers found that 519 of 2,662 women (19.5 percent) had 745 BI-RADS category 3 breast lesions. Of the 745 category 3 lesions, 124 (16.6 percent) were biopsied, and six lesions (0.8 percent; 95 percent confidence interval, 0.3 to 1.7 percent) were malignant. Among the six , one was biopsied at six-month follow-up (N0), one at one-year follow-up (N0), and one at two-year follow-up (N1).

"Since BI-RADS category 3 lesions have a low malignancy rate (0.8 percent; 95 percent confidence interval, 0.3 to 1.7 percent) (six of 745 lesions) and since only one (0.1 percent) lesion had suspicious changes at short-interval follow-up and one (0.1 percent) lesion had suspicious changes at one-year follow-up, both of which showed signs of node-negative , a recommendation of yearly follow-up for BI-RADS category 3 lesions may be appropriate," the authors write.

Several authors disclosed financial ties to biomedical companies, including makers of ultrasound equipment.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Study examines BI-RADS and MRI in predicting breast cancer

May 15, 2012

A large, multicenter study found that the Breast Imaging and Reporting Data Systems (BI-RADS) terminology used by radiologists to classify breast imaging results is useful in predicting malignancy in breast lesions detected ...

Recommended for you

Cancer stem cells linked to drug resistance

17 hours ago

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered ...

Unraveling the 'black ribbon' around lung cancer

Apr 17, 2014

It's not uncommon these days to find a colored ribbon representing a disease. A pink ribbon is well known to signify breast cancer. But what color ribbon does one think of with lung cancer?

User comments